Core Insights - Avantor, Inc. (AVTR) reported a fourth-quarter 2025 adjusted earnings per share (EPS) of 22 cents, a decrease of 18.5% year over year, but exceeded the Zacks Consensus Estimate by 4.8% [1] - The company's revenues for the quarter were $1.66 billion, down 1.4% year over year, yet surpassed the Zacks Consensus Estimate by 3% [2] - Despite beating estimates, shares of Avantor fell 13.6% following the earnings report [2][8] Revenue Details - Revenues of $1.66 billion reflected a 1.4% decline year over year, with a 4.1% organic sales decline after accounting for a positive foreign currency impact of 3.1% and a negative M&A impact of 0.4% [2] - The Laboratory Solutions segment reported net sales of $1.12 billion, down 0.9% year over year, with organic sales decreasing by 4.1% [3][4] Segment Analysis - The Laboratory Solutions segment showed mixed performance, with organic revenues declining 4% year over year, although there was modest sequential improvement [4] - The Bioscience Production segment's net sales were $547.5 million, down 2.4%, with organic sales also decreasing by 4.1% year over year [5][6] Margin Analysis - Avantor's gross profit declined 6.9% year over year to $523.9 million, with a gross margin contraction of 190 basis points to 31.5% [7] - Selling, general and administrative expenses increased by 5.7% year over year to $392.4 million, leading to an adjusted operating profit of $225.4 million, down 19.3% from the prior year [7] Financial Position - At the end of Q4 2025, Avantor had cash and cash equivalents of $365.4 million, up from $251.9 million at the end of Q3 2025, while total debt increased to $3.95 billion from $3.86 billion [9] 2026 Guidance - Avantor projects organic revenue growth to be between negative 2.5% and negative 0.5% for 2026, with adjusted EPS expected to range from 77 cents to 83 cents, below the Zacks Consensus Estimate of 89 cents [11][13] - The company anticipates that the VWR distribution business will modestly outperform Bioscience and Medtech Products, despite ongoing market pressures [11] Strategic Initiatives - Management emphasized a comprehensive "Avantor Revival" initiative aimed at operational improvement and sustainable growth, with significant investments planned to enhance operational efficiency and digital capabilities [16][17] - The company has achieved approximately $265 million in run-rate savings through cost discipline measures, although these have been partially offset by unfavorable mix and pricing actions [16]

Q4 & FY 2025 Earnings Earnings Presentation February 11, 2026 Disclaimer Forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this presentation are forward-looking statements. Forward-l ...

Core Insights - Avantor, Inc. reported a revenue of $1.62 billion for the quarter ended September 2025, reflecting a decline of 5.3% year-over-year and a surprise of -1.56% compared to the Zacks Consensus Estimate of $1.65 billion [1] - The earnings per share (EPS) for the quarter was $0.22, down from $0.26 in the same quarter last year, with an EPS surprise of -4.35% against the consensus estimate of $0.23 [1] Revenue Performance - Bioscience Production revenue was $527.3 million, slightly below the average estimate of $536.7 million, representing a year-over-year decline of 2.9% [4] - Laboratory Solutions revenue totaled $1.1 billion, compared to the average estimate of $1.11 billion, marking a year-over-year decrease of 6.4% [4] Operating Income - Adjusted Operating Income for Laboratory Solutions was reported at $123.6 million, below the average estimate of $134.01 million [4] - Adjusted Operating Income for Corporate was -$14 million, better than the average estimate of -$19.3 million [4] - Adjusted Operating Income for Bioscience Production was $127.7 million, compared to the average estimate of $134.34 million [4] Stock Performance - Avantor's shares have returned +20.8% over the past month, significantly outperforming the Zacks S&P 500 composite's +3.8% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Q3 2025 Earnings Earnings Presentation October 29, 2025 Disclaimer Forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this presentation are forward-looking statements. Forward-looking ...

Core Viewpoint - Avantor Inc. reported worse-than-expected second-quarter 2025 adjusted EPS, leading to a decline in stock price, with shares nearing their 52-week low [1]. Financial Performance - The company reported adjusted EPS of 24 cents, slightly below the consensus estimate of 25 cents [1]. - Sales for the quarter were $1.68 billion, nearly in line with the consensus of $1.675 billion, but fell 1% compared to the second quarter of 2024 [1][2]. - Net income decreased to $64.7 million from $92.9 million a year ago, while adjusted net income was $161.2 million compared to $168 million [5]. - Adjusted EBITDA was $279.8 million, down from $305.6 million, with a margin of 16.6% [5]. - Adjusted operating income fell from $277.2 million to $252.2 million, with a margin of 15.0% [6]. Segment Performance - Laboratory Solutions sales were $1.12 billion, a reported decrease of 3%, with a 1% organic decline [2]. - Bioscience Production sales were $561.3 million, also a reported decrease of 3%, but showed a 2% increase on an organic basis [3]. - The bioprocessing performance did not meet expectations due to planned maintenance at a manufacturing facility, despite strong demand for the monoclonal antibody platform [4]. Strategic Developments - The company announced significant actions to accelerate growth and enhance its cost structure, targeting $400 million in gross run-rate savings by the end of 2027 [6]. - A five-year contract extension with BIO Business Solutions was executed, positioning the company to benefit from future funding levels in the biotech industry [7]. Market Position - Avantor stock trades at approximately 10.8 times the 2025 EBITDA estimate, compared to peers at 15.4 times and its own average of 15.9 times as a public company [8]. - The company's growth and margin profile are considered below peer levels, justifying the current discount to peers [8].

Core Insights - Avantor, Inc. reported revenue of $1.68 billion for the quarter ended June 2025, reflecting a decrease of 1.1% year-over-year, with EPS at $0.24 compared to $0.25 in the same quarter last year [1] - The reported revenue met the Zacks Consensus Estimate, showing a surprise of +0.38%, while the EPS fell short of expectations by 4% [1] Revenue Breakdown - Bioscience Production revenue was $561.3 million, slightly below the estimated $568.43 million, marking a year-over-year increase of +2.6% [4] - Laboratory Solutions revenue reached $1.12 billion, exceeding the average estimate of $1.11 billion, but represented a year-over-year decline of -2.9% [4] Operating Income Analysis - Adjusted Operating Income for Laboratory Solutions was reported at $133.3 million, below the average estimate of $144.2 million [4] - Adjusted Operating Income for Corporate was -$20.8 million, worse than the average estimate of -$17.99 million [4] - Adjusted Operating Income for Bioscience Production was $139.7 million, slightly above the estimated $134.75 million [4] Stock Performance - Avantor's shares have returned -3.2% over the past month, contrasting with the Zacks S&P 500 composite's +2.3% change [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance relative to the broader market in the near term [3]